On April 10, the Centers for Medicare and Medicaid Services released its proposed rule for the Fiscal Year 2027 Inpatient Prospective Payment System. Buried in a 2,000 page document is a proposal that will reshape how new medical devices reach Medicare patients.
CMS is proposing to repeal what’s called the “alternative pathway” for new technology add on payments, known as NTAP. Since 2021, devices that received “breakthrough” designation from the FDA have been able to qualify for supplementary Medicare payments by demonstrating one thing: that they are expensive. They did not have to prove they were clinically better than what already existed. Just newer. Just costlier.
Under the proposed rule, that fast track would be eliminated beginning in FY 2028. Going forward, breakthrough devices would have to meet the same three part test as everything else: new, costly, and clinically superior to existing alternatives. Comments are due to CMS by June 9.
Here’s the wrinkle. The alternative pathway was created during the first Trump administration. The proposal to repeal it is coming from the second Trump administration. This is not a partisan reversal. It is a reconsideration, and the agency’s own justification is unusually thin for a policy of this magnitude.
HOW THIS HELPS PATIENTS
This is the part of the story that most coverage is missing.
Patients have been told for years that “breakthrough” means “better.” It does not. The FDA’s breakthrough designation is about speed of review, not proof of effectiveness. Of the 1,226 breakthrough device designations issued through the end of 2024, many have reached the market without comparative evidence showing they outperform what’s already available. Patients have been receiving these devices, and Medicare has been paying premium rates for them, on the strength of a label, not the strength of the data.
Tightening the standard means that when a Medicare patient receives a device paid at a premium rate, there is actual evidence that the device is worth the premium. That is a win for patients who have been quietly subsidizing innovation theater with their tax dollars and their bodies.
The counter argument matters too. Some breakthrough devices treat conditions where alternatives are inadequate or nonexistent. Rare diseases, hard to reach tumors, treatment resistant infections. For those patients, the fast track has meant earlier access to something genuinely lifesaving. The proposal does grandfather in devices already approved or under review for FY 2027, which softens the blow.
IMPACT ON INSURANCE COMPANIES
For Medicare itself, the insurer in this case, the repeal is a cost control measure with teeth. The NTAP program adds payments on top of standard reimbursement, sometimes substantially. Eliminating the alternative pathway tightens the spigot.
For commercial insurers, the ripple effect is bigger than it looks. Commercial plans often follow Medicare’s lead on coverage and payment policy. When Medicare signals that breakthrough designation alone is not enough to justify premium payment, private insurers gain cover to deny or reduce payment for the same devices in their own networks. Expect to see prior authorization requirements expand around breakthrough devices over the next 18 months. Expect coverage denials to follow.
Medicare Advantage plans win twice. They get federal payment policy that supports tighter device management, and they get the political cover to apply that tightening to their members.
IMPACT ON HEALTHCARE ORGANIZATIONS
This is where the proposal lands hardest, and where most of the public conversation is wrong.
Healthcare organizations are not the villains here. They are the buffer. When a new device is approved and a patient needs it, organizations have to decide whether to stock it, train staff on it, and integrate it into care pathways. Those decisions cost money before a single patient is treated. NTAP payments have helped close the gap between what a device costs and what Medicare pays, making it financially feasible to bring promising new technology into care.
Repealing the alternative pathway shifts more of that financial risk onto the organizations themselves. When the add on payment disappears, the cost of the device does not. Someone has to absorb the difference. In rural and safety net settings, where margins are already negative for a meaningful share of facilities, the answer will increasingly be: we don’t bring this device in at all.
The patients who lose access first will be the ones who already have the least.
MY TAKE
I want a higher evidentiary bar before Medicare pays premium rates for a device. Patients deserve to know that “breakthrough” means something, and right now it doesn’t always.
Look at how the rest of the developed world handles this. In Germany, France, the United Kingdom, and most of Europe, a new device or drug doesn’t get premium payment unless it can demonstrate superiority over existing options. They call it comparative effectiveness, and they treat it as a baseline expectation, not an aspiration. We are the outlier. We have been paying premium prices for “new” without asking “better,” and patients have been footing the bill in the form of higher premiums, higher deductibles, and a Medicare trust fund that runs out faster every year.
There is also a piece of this that almost no one talks about. The foundational science behind most of these devices was paid for by us. The National Institutes of Health funds the basic research that makes breakthrough technology possible. Taxpayers underwrite the discovery. Then a company packages it, runs it through the breakthrough designation pathway, and charges Medicare a premium for the privilege of buying back what we already funded. We pay twice. Once at the lab bench, again at the bedside. Asking for proof that a device actually works better before we pay that second premium is not a high bar. It is the bar.
But I am uneasy about how this proposal arrived. CMS gave the public a sweeping change in innovation policy with thin reasoning, a tight comment window, and no companion plan for how genuinely novel devices for genuinely underserved populations will reach patients without the alternative pathway. “Tighten the standard” is the right instinct. “Tighten the standard without saying what comes next” is how good ideas become bad policy.
There is a version of this rule I would support enthusiastically. Keep the alternative pathway for devices treating conditions with no adequate alternative. Apply the stricter standard everywhere else. Pair the change with a real evidence development pathway, funded, so the comparative data we need actually gets generated.
That is not what CMS proposed. What CMS proposed is a repeal with a six week comment period and a vague promise to align payment with value. That is not policy. That is paperwork.
Comments are due June 9. If you work in medtech, in patient advocacy, in policy, write something. The comment record matters more on rules like this than people realize, because the agency’s reasoning is thin enough that it could be moved. This is the moment.